(Q36544977)

14 August 2017

1 reference

title

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors (English)

1 reference

14 August 2017

1 reference

Qing Ma

1

1 reference

14 August 2017

Olanrewaju O Okusanya

2

1 reference

14 August 2017

Patrick F Smith

3

1 reference

14 August 2017

Robert Dicenzo

4

1 reference

14 August 2017

Judianne C Slish

5

1 reference

14 August 2017

Linda M Catanzaro

6

1 reference

14 August 2017

Alan Forrest

7

1 reference

14 August 2017

Gene D Morse

8

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

Expert Opinion on Drug Metabolism & Toxicology

14 August 2017

published in

1 reference

14 August 2017

volume

1

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

473-485

1 reference

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Drug interactions with antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Failure of treatment of tuberculous adenitis due to an unexpected drug interaction with rifabutin and efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Drug interactions between antiretroviral drugs and comedicated agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Antifungal use in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Methadone--metabolism, pharmacokinetics and interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Anticonvulsant and antiretroviral interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Significant interactions with new antiretrovirals and psychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Management of protease inhibitor-associated hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Delavirdine: a review of its use in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Indinavir concentrations and St John's wort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

St Johns wort increases expression of P-glycoprotein: implications for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

The effect of garlic supplements on the pharmacokinetics of saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Therapeutic drug monitoring in HIV infection: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Therapeutic drug monitoring in the treatment of HIV-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.473

21 January 2018

Identifiers

DOI

10.1517/17425255.1.3.473

1 reference

14 August 2017

1 reference